The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Evaluation of Cytochrome P450 Probe Substrates Commonly Used by the Pharmaceutical Industry to Study in Vitro Drug Interactions
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785 · cited 3×
“(Shimada et al., 1994), it is responsible for metabolizing drugs in a”
BackgroundInfluentialButler, M. A., Iwasaki, M., Guengerich, F. P., & Kadlubar, F. F. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.20.7696 · Cited by 638
Newton, D. J., Wang, R. W., & Lu, A. Y. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06500-6 · Cited by 605
Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., & Trager, W. F. (1992) · Chemical Research in Toxicology · doi:10.1021/tx00025a009 · Cited by 601
Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.
Kronbach, T., Mathys, D., Umeno, M., Gonzalez, F. J., & Meyer, U. A. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09118-7 · Cited by 532
Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1
Peter, R., Boecker, R., Beaune, P. H., Iwasaki, M., Guengerich, F. P., & Yang, C. S. (1990) · Chemical Research in Toxicology · doi:10.1021/tx00018a012 · Cited by 528
Gorski, J. C., Jones, D. R., Haehner-Daniels, B. D., Hamman, M. A., O'Mara, E. M., & Hall, S. D. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90146-1 · Cited by 411
Cooperativity in Oxidations Catalyzed by Cytochrome P450 3A4
Ueng, Y.-F., Kuwabara, T., Chun, Y.-J., & Guengerich, F. P. (1997) · Biochemistry · doi:10.1021/bi962359z · Cited by 383
Bourrié, M., Meunier, V, Berger, Y., & Fabre, G. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12826-7 · Cited by 363
Chauret, N., Gauthier, A., & Nicoll‐Griffith, D. A. (1998) · PubMed · Cited by 357
CYP3A4 drug interactions: correlation of 10 in vitro probe substrates
Kenworthy, Bloomer, Clarke, & Houston (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00073.x · Cited by 336
Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s
Waxman, D. J., Lapenson, D. P., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., & Korzekwa, K. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90602-f · Cited by 324
Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2.
Tassaneeyakul, W., Birkett, D. J., Veronese, M. E., McManus, M. E., Tukey, R. H., Quattrochi, L. C., Gelboin, H. V., & Miners, J. O. (1993) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38136-x · Cited by 316
Yamazaki, H., & Shimada, T. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.0302 · Cited by 310
Busby, W. F., Ackermann, J. M., & Crespi, C. L. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15284-1 · Cited by 307
Tucker, G. T., Houston, J. B., & Huang, S. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.temp.1441.x · Cited by 284
Self-citationWrighton, S. A., Stevens, J. C., Becker, G. W., & Vandenbranden, M. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1506 · Cited by 281
Stresser, D. M., Blanchard, A. P., Turner, S. D., Erve, J. C. L., Dandeneau, A. A., Miller, V. P., & Crespi, C. L. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)13672-0 · Cited by 273
Kronbach, T., Mathys, D., Gut, J., Catin, T., & Meyer, U. A. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90006-6 · Cited by 261
Shimada, T., Misono, K. S., & Guengerich, F. P. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36183-5 · Cited by 256
Gibbs, M. A., Thummel, K. E., Shen, D. D., & Kunze, K. L. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15274-9 · Cited by 245
Human Cytochrome P-450 3A4: In Vitro Drug-Drug Interaction Patterns Are Substrate-Dependent
Wang, R. W., Newton, D. J., Liu, N., Atkins, W. M., & Lu, A. Y. H. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15374-3 · Cited by 240
Sesardic, D., Boobis, A., Edwards, R., & Davies, D. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03393.x · Cited by 233
Identification of a polymorphically expressed member of the human cytochrome P-450III family.
Wrighton, S. A., Ring, B. J., Watkins, P. B., & VandenBranden, M. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09114-x · Cited by 228
Hickman, D., Wang, J. P., Wang, Y., & Unadkat, J. D. (1998) · PubMed · Cited by 222
Tolbutamide hydroxylation by human liver microsomes
Miners, J. O., Smith, K. J., Robson, R. A., McManus, M. E., Veronese, M. E., & Birkett, D. J. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90522-9 · Cited by 198
Caffeine metabolism by human hepatic cytochromes p450: Contributions of 1A2, 2E1 and 3A isoforms
Tassaneeyakul, W., Birkett, D. J., McManus, M. E., Tassaneeyakul, W., Veronese, M. E., Andersson, T., Tukey, R. H., & Miners, J. O. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90304-2 · Cited by 198
Ghosal, A., Satoh, H., Thomas, P. E., Bush, E., & Moore, D. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07487-2 · Cited by 193
Inhibition of Coumarin 7-Hydroxylase Activity in Human Liver Microsomes
Draper, A. J., Madan, A., & Parkinson, A. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.9964 · Cited by 191
Yumoto, R., Murakami, T., Nakamoto, Y., Hasegawa, R., Nagai, J., & Takano, M. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38117-0 · Cited by 184
Kunze, K. L., Wienkers, L. C., Thummel, K. E., & Trager, W. F. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07368-4 · Cited by 161
Tucker, G. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.116891 · Cited by 154
Lasker, J. M., Wester, M. R., Aramsombatdee, E., & Raucy, J. L. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0615 · Cited by 150
CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans
Jacqz-Aigrain, É., Funck‐Brentano, C., & Cresteil, T. (1993) · Pharmacogenetics · doi:10.1097/00008571-199308000-00004 · Cited by 147
Wrighton, S. A., & Ring, B. J. (1994) · Pharmaceutical Research · doi:10.1023/a:1018906614320 · Cited by 145
The warfarin-sulfinpyrazone interaction: stereochemical considerations
Toon, S., Low, L. K., Gibaldi, M., Trager, W. F., O’Reilly, R. A., Motley, C. H., & Goulart, D. A. (1986) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1986.3 · Cited by 144
Takano, M., Hasegawa, R., Fukuda, T., Yumoto, R., Nagai, J., & Murakami, T. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00607-4 · Cited by 141
Inoue, K., Yamazaki, H., Imiya, K., Akasaka, S., Guengerich, F. P., & Shimada, T. (1997) · Pharmacogenetics · doi:10.1097/00008571-199704000-00003 · Cited by 135
Edwards, R. J., Adams, D. A., Watts, P. S., Davies, D. S., & Boobis, A. R. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00033-1 · Cited by 134
Yamazaki, H., Inoue, K., Shaw, P. M., Checovich, W. J., Guengerich, F. P., & Shimada, T. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37072-7 · Cited by 133
Drug Interactions and the Cytochrome P450 System
Brøsen, K. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199500291-00005 · Cited by 131
Shimada, T., Yamazaki, H., & Guengerich, F. P. (1996) · Xenobiotica · doi:10.3109/00498259609046718 · Cited by 130
Moltke, L. L., Greenblatt, D. J., Duan, S. X., Schmider, J., Kudchadker, L., Fogelman, S. M., Harmatz, J. S., & Shader, R. I. (1996) · Psychopharmacology · doi:10.1007/s002130050149 · Cited by 115
Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1
Ono, S., Hatanaka, T., Hotta, H., et al. (1995) · Pharmacogenetics · doi:10.1097/00008571-199506000-00002 · Cited by 113
Gut, J., Catin, T., Dayer, P., Kronbach, T., Zanger, U. M., & Meyer, U. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67305-3 · Cited by 111
Monospecific Antipeptide Antibody to Cytochrome P-450 2B6
Stresser, D. M., & Kupfer, D. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15215-4 · Cited by 111
Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin.
Heyn, H., White, R. B., & Stevens, J. C. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07488-4 · Cited by 109
Tassaneeyakul, W., Mohamed, Z., Birkett, D., McManus, M. E., Veronese, M. E., Tukey, R. H., Quattrochi, L. C., Gonzalez, F. J., & Miners, J. O. (1992) · Pharmacogenetics · doi:10.1097/00008571-199208000-00004 · Cited by 103
Boobis, A. R., Kahn, G. C., Whyte, C., Brodie, M. J., & Davies, D. S. (1981) · Biochemical Pharmacology · doi:10.1016/0006-2952(81)90340-3 · Cited by 89
Drug Interactions and the Cytochrome P450 System
Flockhart, D. A. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199500291-00008 · Cited by 84
[15] Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9
Miners, J. O., & Birkett, D. (1996) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(96)72017-7 · Cited by 82
Hemeryck, A., Vriendt, C. D., & Belpaire, F. M. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050580 · Cited by 81
Biotransformation of caffeine by microsomes from human liver
Grant, D. M., Campbell, M. E., Tang, B. K., & KALOW, W. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90078-5 · Cited by 78
Venkatakrishnan, K., Moltke, L. L., & Greenblatt, D. J. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980255z · Cited by 77
CYP2C19 Participates in Tolbutamide Hydroxylation by Human Liver Microsomes
Wester, M. R., Lasker, J. M., Johnson, E. F., & Raucy, J. L. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15373-1 · Cited by 71
Tang, C., Shou, M., & Rodrigues, A. D. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15101-x · Cited by 69
Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes.
Hall, S. D., Guengerich, F. P., Branch, R. A., & Wilkinson, G. R. (1987) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22676-3 · Cited by 68
Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone
Gorski, J. C., JONES, D. R., Wrighton, S. A., & Hall, S. D. (1997) · Xenobiotica · doi:10.1080/004982597240578 · Cited by 67
Inhibitory effects of antiarrhythmic drugs on phenacetin O‐deethylation catalysed by human CYP1A2
Kobayashi, K., Nakajima, M., Chiba, K., et al. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.t01-1-00692.x · Cited by 64
Mei, Q., Tang, C., Assang, C., et al. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35163-8 · Cited by 59
Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6.
Ko, J.-W., Desta, Z., & Flockhart, D. A. (1998) · PubMed · Cited by 58
Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4
Gelboin, H. V., Krausz, K. W., Goldfarb, I. S., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02077-2 · Cited by 51
In vitro metabolic interaction studies: Experience of the Food and Drug Administration
Yuan, R., PARMELEE, T., Balian, J. D., Uppoor, R. S., Ajayi, F., Burnett, A. L. “., Lesko, L. L., & Marroum, P. J. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70048-2 · Cited by 48
Self-citationShou, M., Lu, T., Krausz, K. W., Sai, Y., Yang, T., Korzekwa, K. R., Gonzalez, F. J., & Gelboin, H. V. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00079-0 · Cited by 47
The Role of CYP2C19 in the Metabolism of (+/–) Bufuralol, the Prototypic Substrate of CYP2D6
Mankowski, D. C. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15021-0 · Cited by 45
S-mephenytoin 4-hydroxylation in older Americans
Pollock, B. G., Perel, J. M., Kirshner, M. A., et al. (1991) · European Journal of Clinical Pharmacology · doi:10.1007/bf00279979 · Cited by 34
Li, Y., Li, N.-Y., & Sellers, E. M. (1997) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190960 · Cited by 33
Digitalis enhances exercise-induced hyperkalaemia
N�rgaard, A., B�tker, H. E., Klitgaard, N. A., & Toft, P. (1991) · European Journal of Clinical Pharmacology · doi:10.1007/bf00314994 · Cited by 17
Cited by
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part I
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318030-000000000-00000 · Cited by 756
Inhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 569
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs
Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M., & McLeod, H. L. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544030-00005 · Cited by 517
VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES
Walsky, R. L., & Obach, R. S. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.647 · Cited by 507
Metadata
- Authors
- Yuan, R., Madani, S., Wei, X.-X., Reynolds, K., & Huang, S.-M.
- Venue
- Drug Metabolism and Disposition
- Publisher
- Elsevier BV
- Published
- 2002-12
- Volume
- 30
- Issue
- 12
- Pages
- 1311-1319
- ISSN
- 0090-9556 (ISSN-L)
- OpenAlex
- W2163536623
- Cited by
- 325
- References
- 68
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.